Moderna combination Covid, flu vaccine moves to final stage trial after positive data
Publishing timestamp: 2023-10-04 07:00:01
Summary
Moderna's combination vaccine targeting Covid and flu has shown positive results in an early study and will now move to the final stage trial. The company hopes to win approval from regulators in 2025. Moderna and other vaccine makers believe combination shots will simplify protection against respiratory viruses that surge at the same time of year. The combination vaccine generated a strong immune response and had similar safety data to Moderna's stand-alone Covid shot. Moderna is also developing a combination shot targeting flu and RSV, as well as a vaccine targeting all three respiratory viruses. Pfizer and BioNTech are also developing a vaccine targeting both Covid and flu.
Sentiment: POSITIVE
Tickers: MRNA, PFE, GSK-GB, GSK, BNTX,
Keywords: pfizer inc, breaking news, biotech and pharmaceuticals, biotechnology, science, moderna inc, business news, gsk plc, health care industry, biontech se, business, pharmaceuticals,
Source: https://www.cnbc.com/2023/10/04/moderna-combination-covid-flu-vaccine-shows-positive-data.html